Pharsight

1. Brixadi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545832	BRAEBURN	Lipid depot formulations	Jun, 2025 (1 year, 1 month from now)
US8236755	BRAEBURN	Opioid depot formulations	Jul, 2026 (2 years from now)
US8236292	BRAEBURN	Liquid depot formulations	Jan, 2027 (2 years from now)
US9937164	BRAEBURN	Opioid formulations	Jul, 2032 (8 years from now)
US11110084	BRAEBURN	Opioid formulations	Jul, 2032 (8 years from now)
US11135215	BRAEBURN	Opioid formulations	Jul, 2032 (8 years from now)
US10912772	BRAEBURN	Opioid formulations	Jul, 2032 (8 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 23, 2026

Market Authorisation Date: 23 May, 2023

Treatment: A method of delivery of a bioactive agent by subcutaneous injection. a method of treatment of a human for addiction; A method of delivery of an opioid bioactive agent. a method of treatment or prophyl...

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
8MG/0.16ML (50MG/ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription
128MG/0.36ML (356MG/ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription
96MG/0.27ML (356MG/ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription
64MG/0.18ML (356MG/ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription
24MG/0.48ML (50MG/ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription
16MG/0.32ML (50MG/ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription
32MG/0.64ML (50MG/ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription

BRIXADI family patents

2. Butrans patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6264980	PURDUE PHARMA LP	Transdermal resorption of active substances from supercooled masses of levulic acid	Dec, 2015 (8 years ago)
US6344211	PURDUE PHARMA LP	Transdermal absorption of active substances from subcooled melts	Dec, 2015 (8 years ago)
USRE41489	PURDUE PHARMA LP	Method of providing sustained analgesia with buprenorphine	Sep, 2017 (6 years ago)
USRE41571	PURDUE PHARMA LP	Method of providing sustained analgesia with buprenorphine	Sep, 2017 (6 years ago)
USRE41408	PURDUE PHARMA LP	Method of providing sustained analgesia with buprenorpine	Sep, 2017 (6 years ago)
US9642850	PURDUE PHARMA LP	Method of providing sustained analgesia with buprenorphine	Sep, 2017 (6 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-250)	Oct 13, 2020
New Dosage Form(NDF)	Jun 30, 2013

Market Authorisation Date: 30 June, 2010

Treatment: The management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time; Management of pain severe enough to require dail...

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mcg/hr 10 mcg/hr 20 mcg/hr	06 Jun, 2013	1	20 Nov, 2018	29 Sep, 2017	Extinguished
15 mcg/hr	16 Dec, 2013	1	20 Nov, 2018	29 Sep, 2017	Extinguished

Strength	Dosage	Availability
15MCG/HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
10MCG/HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
7.5MCG/HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
20MCG/HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
5MCG/HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

BUTRANS family patents

3. Sublocade patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP15828368A	2021-03-30	ELKINGTON AND FIFE LLP	Granted and Under Opposition
EP11728037A	2018-10-10	Teva Pharmaceutical Industries Ltd.	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9827241	INDIVIOR	Injectable flowable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US9498432	INDIVIOR	Injectable flowable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US9272044	INDIVIOR	Injectable flowable composition buprenorphine	Jun, 2031 (7 years from now)
US9782402	INDIVIOR	Injectable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US10198218	INDIVIOR	Injectable flowable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US10592168	INDIVIOR	Injectable flowable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US10558394	INDIVIOR	Injectable flowable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US8975270	INDIVIOR	Injectable flowable composition comprising buprenorphine	Sep, 2031 (7 years from now)
US8921387	INDIVIOR	Injectable flowable composition comprising buprenorphine	Jan, 2032 (7 years from now)
US11000520	INDIVIOR	Buprenorphine dosing regimens	Nov, 2035 (11 years from now)
US11839611	INDIVIOR	Buprenorphine dosing regimens	Nov, 2035 (11 years from now)
US10646484	INDIVIOR	Methods to treat opioid use disorder	Jun, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 30, 2020

Market Authorisation Date: 30 November, 2017

Treatment: Treating opioid addiction by 100 mg or 300 mg dose buprenorphine; In situ formation of solid buprenorphine composition; Treating opioid addiction by subcutaneous injection of buprenorphine; Treating a...